Peptides for Fertility: Kisspeptin, GnRH Analogs, CJC-1295, and Reproductive Health

Infertility affects approximately 15% of couples worldwide — roughly 48 million couples — with causes distributed broadly across male and female factors. While assisted reproductive technology (ART) has transformed outcomes for many, the underlying biological contributors to infertility often remain inadequately addressed. Peptides that directly regulate reproductive hormone axes, support gonadal function, and address systemic factors affecting fertility represent a growing area of clinical and research interest.

This article reviews the most evidence-supported peptides for fertility: kisspeptin, GnRH analogs, CJC-1295/ipamorelin, and BPC-157.

The Reproductive Hormone Axis

Fertility depends on a precisely regulated neuroendocrine cascade:

1. Kisspeptin neurons in the hypothalamus receive metabolic, hormonal, and environmental signals and modulate GnRH release
2. GnRH (gonadotropin-releasing hormone) is released in pulses from the hypothalamus to the pituitary
3. LH and FSH are released by the pituitary in response to GnRH
4. LH drives testosterone production in Leydig cells (men) and triggers ovulation (women)
5. FSH drives spermatogenesis (men) and follicular development (women)

Disruption at any point in this cascade can impair fertility. Many peptides work by restoring function at specific nodes of this axis.

Kisspeptin: The Master Regulator of GnRH

Kisspeptin — encoded by the KISS1 gene — is now recognized as the dominant regulator of GnRH secretion. Without kisspeptin signaling, GnRH neurons are essentially silent. This discovery, made in the early 2000s following observations that KISS1 receptor mutations cause hypogonadotropic hypogonadism, transformed reproductive neuroendocrinology.

Kisspeptin in female fertility: Kisspeptin neurons mediate the estrogen-positive feedback mechanism that triggers the LH surge responsible for ovulation. In women with hypothalamic amenorrhea — where chronic energy deficit, exercise, or stress suppresses the hypothalamic-pituitary-ovarian axis — kisspeptin levels are low and the LH surge fails to occur.

Clinical evidence in IVF: A landmark study by Jayasena et al. (2014) published in the Journal of Clinical Investigation demonstrated that kisspeptin-54 injection in women undergoing IVF stimulated the LH surge and successful egg maturation with a favorable safety profile compared to standard hCG trigger (which carries ovarian hyperstimulation syndrome risk). Subsequent trials confirmed kisspeptin as a safer alternative trigger in high-risk IVF patients.

Hypothalamic amenorrhea: Multiple studies show kisspeptin-54 infusion restores LH pulsatility in women with hypothalamic amenorrhea, suggesting it can "reboot" a suppressed reproductive axis. This is particularly relevant for athletes, women with low body weight, and those recovering from eating disorders.

Kisspeptin in male fertility: In men, kisspeptin regulates testosterone production through LH stimulation. Low kisspeptin signaling contributes to secondary hypogonadism. Kisspeptin-10 administration in healthy men produces significant LH and testosterone elevation within hours.

GnRH Analogs: Pulsatile Versus Suppressive Use

GnRH itself, and its analogs, have a paradoxical biology: pulsatile administration stimulates gonadotropin release, while continuous administration suppresses it (downregulating pituitary GnRH receptors).

Pulsatile GnRH for hypogonadotropic hypogonadism: For men and women with GnRH deficiency (Kallmann syndrome, hypothalamic amenorrhea), pulsatile GnRH delivery via pump is an established fertility treatment. It restores physiological LH and FSH pulsatility and leads to spermatogenesis in men and follicular development and ovulation in women — often with higher quality outcomes than direct gonadotropin injection.

GnRH agonists in IVF: Leuprolide and other GnRH agonists are used in IVF protocols to suppress premature LH surges during ovarian stimulation. This is continuous, suppressive use — the opposite of pulsatile.

GnRH antagonists: Cetrorelix and ganirelix are used in antagonist IVF protocols to prevent premature ovulation. They provide flexible, rapid suppression without the initial flare associated with agonists.

CJC-1295 and Ipamorelin: GH Axis Support for Fertility

The connection between growth hormone and fertility is underappreciated. GH and IGF-1 play important roles in:

• Follicular development and oocyte quality in women
• Spermatogenesis and testosterone production in men
• Endometrial receptivity for implantation
• Hypothalamic-pituitary sensitivity to gonadotropins

GH-deficient patients: Women with GH deficiency have significantly reduced IVF success rates. GH adjuvant therapy in poor IVF responders is supported by meta-analyses showing improved clinical pregnancy rates (approximately 20% higher live birth rates in poor responders receiving adjuvant GH).

GH secretagogues for fertility: CJC-1295 combined with ipamorelin stimulates physiological GH pulsatility. For individuals with age-related GH decline or documented poor response to ovarian stimulation, normalizing GH/IGF-1 through secretagogues may improve follicular quality and endometrial function without the risks of pharmacological GH doses.

Male applications: GH supports Sertoli cell function and spermatogenesis. Men with idiopathic oligospermia and low IGF-1 may benefit from GH axis support. See our CJC-1295 guide and ipamorelin guide for details.

BPC-157: Reproductive Tissue and Endocrine Support

BPC-157 is not a reproductive hormone per se, but its broad cytoprotective and systemic effects have several fertility-relevant applications.

Endometrial health: BPC-157 promotes angiogenesis and tissue healing. The endometrium requires adequate vascularization for implantation — thin or poorly vascularized endometrium is a common cause of implantation failure. BPC-157's angiogenic properties may support endometrial receptivity, though specific IVF studies are lacking.

Testicular protection: Animal research shows BPC-157 protects against testicular damage from toxins and ischemia. It supports Leydig and Sertoli cell function and may mitigate the gonadotoxic effects of environmental toxins, obesity-related inflammation, and oxidative stress — all contributors to male infertility.

Systemic inflammation: Chronic systemic inflammation is an underrecognized contributor to infertility in both sexes. Elevated TNF-α and IL-6 impair folliculogenesis, reduce oocyte quality, and disrupt sperm function. BPC-157's potent anti-inflammatory effects may reduce this biological interference. See our BPC-157 guide.

Gut-hormone axis: BPC-157 modulates the gut-brain axis and serotonergic/dopaminergic tone. Chronic stress suppresses the reproductive axis largely through cortisol and dopamine dysregulation — mechanisms that BPC-157 partially addresses.

Male Fertility Considerations

Male factor infertility — low sperm count, poor motility, abnormal morphology — contributes to approximately 40–50% of infertility cases. Peptide considerations in men include:

Kisspeptin and LH: Kisspeptin stimulates testosterone production via LH. In men with secondary hypogonadism (low testosterone with normal or low LH/FSH), kisspeptin may restore the central drive without suppressing the HPG axis as exogenous testosterone does.

Growth hormone peptides: As noted, GH/IGF-1 support Sertoli cells (which nourish developing sperm) and Leydig cells (testosterone producers). GH secretagogues may complement fertility treatment in men with GH deficiency or poor sperm parameters alongside low IGF-1.

BPC-157: Protective against oxidative damage to sperm DNA — a mechanism relevant to poor morphology and fragmentation.

Peptides vs. testosterone: This is a critical distinction. Exogenous testosterone completely suppresses FSH and LH, causing testicular atrophy and azoospermia. Men wanting to maintain or improve fertility should not use exogenous testosterone. See our peptides vs. steroids guide for context.

Female Fertility: Timing and Ovarian Reserve

Diminished ovarian reserve (DOR): Women with DOR — fewer remaining follicles or reduced oocyte quality — are among the most challenging fertility cases. GH adjuvant therapy has the strongest evidence in this population. Kisspeptin research suggests it may improve LH pulsatility and follicular response in women with hypothalamic dysfunction.

PCOS: Polycystic ovary syndrome is the most common cause of anovulatory infertility. Kisspeptin's role in PCOS is complex — some research shows altered kisspeptin signaling in PCOS. Ongoing trials are investigating kisspeptin as a therapeutic tool in PCOS-associated infertility.

Thyroid and adrenal health: Multiple peptides support thyroid and adrenal function that secondarily affect fertility. Thyroid dysfunction is a common hidden cause of infertility.

Regulatory and Safety Context

Kisspeptin-54 is in active clinical development for fertility applications. GnRH and its analogs are FDA-approved and widely used in reproductive medicine. CJC-1295 and ipamorelin are research compounds without FDA approval for fertility indications. BPC-157 is a research peptide.

All fertility peptide use should be undertaken with reproductive endocrinologist oversight, particularly given the complexity and time-sensitivity of fertility treatment.

Frequently Asked Questions

Q: Can kisspeptin replace hCG as an IVF trigger? Clinical trials have demonstrated kisspeptin-54 as an effective and potentially safer ovulation trigger in IVF, particularly in high-risk patients for OHSS. It has been used in NHS fertility clinics in the UK as part of research protocols and is approaching clinical adoption.

Q: Does CJC-1295/ipamorelin improve egg quality? GH secretagogues may improve oocyte quality by supporting IGF-1 levels, which are important for follicular maturation. The most direct evidence is for exogenous GH in poor responders; GH secretagogues are expected to have similar but more modest effects.

Q: Can men use peptides to boost testosterone without affecting fertility? Kisspeptin and GH secretagogues stimulate endogenous testosterone production without suppressing FSH or spermatogenesis. This makes them preferable to exogenous testosterone for men wishing to maintain fertility.

Q: Is BPC-157 safe during pregnancy? There is insufficient safety data for BPC-157 use during pregnancy. It should be discontinued before conception attempts and is contraindicated during pregnancy until further safety data is available.

Q: How does stress affect fertility and can peptides help? Psychological and physiological stress suppresses kisspeptin neuron activity, reducing GnRH pulsatility and downstream gonadotropin output — a mechanism underlying stress-related hypothalamic amenorrhea. Peptides that buffer the HPA axis (BPC-157, Selank) may indirectly support fertility by reducing the central suppressive effect of stress. See our peptides for depression guide for relevant mechanisms.